For global showcasing of Indian pharma products, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) will organise the iPHEX 2013 - the mega exhibition of Indian pharmaceutical products and technologies-- in Mumbai from April 24 to 26, 2013 in which over 400 leading Indian companies are expected to showcase the best of pharma products.

The event will see the presence of 5000 business visitors including overseas buyers and drug regulators. Huge business opportunities are expected to emerge during the event. Further the presence of large number of drug regulators from overseas market will immensely help Pharmexcil and its members to promote the quality and affordability aspect as envisaged in Brand India Pharma Campaign.

“iPHEX 2013 will be the biggest industry exposition in India showcasing the diverse range of products and will include formulations, APIs, Ayush, nutraceuticals, health services, biotechnology and biotechnology products, R&D services etc.,” informed Bhavin Mehta, committee chief of IPHEX and CoA member, Pharmexcil.

“iPHEX 2013 will be a complete value chain show and Pharmexcil is creating a sustainable pharma industry platform with a special focus on exports market development. The exports growth story is one to be proud of,” said Dr PV Appaji, director general, Pharmexcil.

Elaborating on the strengths of the Indian pharmaceutical industry, Dr Appaji says, “India is the third largest player in the world with 500 different APIs and ranks fourth globally in terms of production volumes; and 13th globally in domestic consumption value. The country is the largest exporter globally of generic formulations in volume. It exports vaccines to 150 countries and produces 40 per cent to 70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccines.”

“Total exports during the last five years have grown by 16 per cent CAGR, growth during the last financial year, 2011-12 was 23.34 per cent in USD terms. North America continues to be our best destination with a CAGR of 25 per cent and 33 per cent growth during 2011-12. Exports to EU has grown exceptionally well during 2011-12 with 28 per cent considering the fact that a single digit CAGR was recorded during the last four years. Exports to Oceania have also grown well with a growth of 43 per cent but the overall turnover is small and considering the fact that Australia and New Zealand are not yet fully tapped, higher growth rates can be expected,” Dr Appaji said.